Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Myriad Genetics Affirms FY2025 Adj EPS Guidance of $(0.02)-$0.02 vs $(0.01) Est; Raises FY2025 Sales Guidance from $807.00M-$823.00M to $818.00M-$828.00M vs $810.40M Est

Author: Benzinga Newsdesk | August 05, 2025 04:09pm
Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs $(0.01) analyst estimate. Raises FY2025 sales outlook from $807.00 million-$823.00 million to $818.00 million-$828.00 million vs $810.40 million estimate.

Posted In: MYGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist